MDxHealth Announces Pricing of Offering of ADSs in the United States

About this update from Mdxhealth Sa

[{"type":"text","content":"NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSsin the United States IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 10,000,000 American Depositary Shares (“ADSs”) (each representing 10 ordinary shares of the Company without nominal value) (the “Offering”) at a price to the public of USD 4.00 per ADS1 for total gross proceeds of USD 40.0 million2 before deducting commissions and estimated offering expenses. In connection with the Offering, mdxhealth has granted the underwriters a 30-day option to purchase 1,500,000 additional ADSs, on the same terms and conditions. The closing of the Offering is expected to occur on February 7, 2023, subject to the satisfaction of customary closing conditions. The new shares underlying the offered ADSs will have the same rights and benefits as, and rank pari passu in all respects, including as to entitlement to dividends and distributions, with, the Company’s existing and outstanding ordinary shares and will be entitled to distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares. Mdxhealth intends to use the net proceeds from the Offering for general corporate and working capital purposes, including to fund product development efforts and commercial activities. Cowen and Company, LLC and William Blair & Company, L.L.C. are acting as joint book-running managers, BTIG, LLC is acting as lead manager and KBC Securities USA LLC is acting as co-manager for the Offering. The ADSs described above are being offered by mdxhealth pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the Offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer...

More updates from Mdxhealth Sa